Cheaper trials do not necessarily mean poorer data—India’s rigorous regulatory standards and large, treatment-naïve patient populations enable high-quality studies at lower operational costs. As a regulator, I’ve reviewed immaculate data from Indian sites that meets our FDA benchmarks. Honestly, this efficiency reminds me of my own family’s resourcefulness back in Delhi, stretching every rupee for my daughter’s future without ever compromising on what truly matters.
#exams#study
Jump in to reply — no account needed.